Patrizia Russo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8016784/publications.pdf

Version: 2024-02-01

172457 197818 2,922 113 29 49 citations h-index g-index papers 116 116 116 4077 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. Lung Cancer, 2007, 57, 175-180.	2.0	154
2	COVID-19 and smoking: is nicotine the hidden link?. European Respiratory Journal, 2020, 55, 2001116.	6.7	142
3	Pre-operative pulmonary rehabilitation and surgery for lung cancer. Lung Cancer, 2007, 57, 118-119.	2.0	126
4	Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance. Current Medicinal Chemistry, 2009, 16, 1688-1703.	2.4	124
5	α7-Nicotinic Acetylcholine Receptors Affect Growth Regulation of Human Mesothelioma Cells. Cancer Research, 2004, 64, 135-145.	0.9	110
6	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	2.5	106
7	Nicotine: specific role in angiogenesis, proliferation and apoptosis. Critical Reviews in Toxicology, 2012, 42, 68-89.	3.9	105
8	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	2.6	81
9	Adding Ipsilateral V20 and V30 to Conventional Dosimetric Constraints Predicts Radiation Pneumonitis in Stage IIIA–B NSCLC Treated With Combined-Modality Therapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 110-115.	0.8	74
10	Natural agents targeting the α7â€nicotinicâ€receptor in NSCLC: A promising prospective in antiâ€cancer drug development. International Journal of Cancer, 2008, 122, 1911-1915.	5.1	73
11	The cholinergic system and cancer. Seminars in Cancer Biology, 2008, 18, 211-217.	9.6	69
12	Tobacco Habit: Historical, Cultural, Neurobiological, and Genetic Features of People's Relationship with an Addictive Drug. Perspectives in Biology and Medicine, 2011, 54, 557-577.	0.5	64
13	Molecular Mechanisms of Hexavalent Chromium–Induced Apoptosis in Human Bronchoalveolar Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 589-600.	2.9	58
14	Nicotine, Lung and Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 461-466.	1.7	54
15	New Drugs from Marine Organisms in Alzheimer's Disease. Marine Drugs, 2016, 14, 5.	4.6	52
16	DNA damage in non-communicable diseases: A clinical and epidemiological perspective. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 776, 118-127.	1.0	50
17	Inhibition of Nonneuronal α7-Nicotinic Receptor for Lung Cancer Treatment. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 1141-1150.	5.6	47
18	α7-Nicotinic receptor antagonists at the beginning of a clinical era for NSCLC and Mesothelioma?. Drug Discovery Today, 2009, 14, 822-836.	6.4	46

#	Article	IF	Citations
19	Nicotinic receptor and tobacco-related cancer. Life Sciences, 2012, 91, 1087-1092.	4.3	46
20	RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: Role of p53. International Journal of Cancer, 2002, 100, 266-275.	5.1	43
21	Anticancer Drug Discovery from the Marine Environment. Recent Patents on Anti-Cancer Drug Discovery, 2012, 7, 218-232.	1.6	43
22	Shorter telomere length in schizophrenia: Evidence from a real-world population and meta-analysis of most recent literature. Schizophrenia Research, 2018, 202, 37-45.	2.0	40
23	Studies on DNA binding of caffeine and derivatives: evidence of intercalation by DNA-unwinding experiments. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1989, 1007, 112-115.	2.4	39
24	P4 Medicine Needs P4 Education. Current Pharmaceutical Design, 2014, 20, 6071-6072.	1.9	37
25	DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. Scientific Reports, 2021, 11, 16793.	3.3	36
26	Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis. Investigational New Drugs, 2011, 29, 98-109.	2.6	35
27	A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases. Current Pharmaceutical Design, 2014, 20, 5945-5956.	1.9	32
28	Role of the Non-Neuronal Human Cholinergic System in Lung Cancer and Mesothelioma: Possibility of New Therapeutic Strategies. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 535-542.	7.0	30
29	Targeting $\hat{l}\pm 7$ -nicotinic receptor for the treatment of pleural mesothelioma. European Journal of Cancer, 2008, 44, 2296-2311.	2.8	29
30	Alkaline DNA fragmentation, DNA disentanglement evaluated viscosimetrically and sister chromatid exchanges, after treatment in vivo with nitrofurantoin. Chemico-Biological Interactions, 1983, 45, 77-94.	4.0	28
31	$\hat{l}\pm 7$ -Nicotinic Acetylcholine Receptors: An Old Actor for New Different Roles. Current Drug Targets, 2012, 13, 574-578.	2.1	28
32	Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 39-52.	1.6	28
33	Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 123-138.	7.0	28
34	Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: Correlations with the formation of DNA double-strand breaks. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 311, 21-29.	1.0	27
35	Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. International Journal of Cancer, 2002, 97, 732-739.	5.1	27
36	Alpha9Alpha10 Nicotinic Acetylcholine Receptors as Target for the Treatment of Chronic Pain. Current Pharmaceutical Design, 2014, 20, 6042-6047.	1.9	26

#	Article	IF	CITATIONS
37	Nicotine upregulates ACE2 expression and increases competence for SARS-CoV-2 in human pneumocytes. ERJ Open Research, 2021, 7, 00713-2020.	2.6	25
38	c-mycDown-Regulation Induces Apoptosis in Human Cancer Cell Lines Exposed to RPR-115135 (C31H29NO4), a Non-Peptidomimetic Farnesyltransferase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 37-47.	2.5	23
39	New Anticancer Drugs from Marine Cyanobacteria. Current Drug Targets, 2012, 13, 1048-1053.	2.1	23
40	Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761 \hat{A}°). Pharmaceuticals, 2021, 14, 305.	3.8	23
41	Beyond Acetylcholinesterase Inhibitors for Treating Alzheimer&aposs Disease: .α7-nAChR Agonists in Human Clinical Trials. Current Pharmaceutical Design, 2014, 20, 6014-6021.	1.9	22
42	Is ?7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?. Current Drug Targets, 2012, 13, 688-694.	2.1	22
43	DNA damage induced by auramine O in liver, kidney, and bone marrow of rats and mice, and in a human cell line (alkaline elution assay and SCE induction). Journal of Toxicology and Environmental Health - Part A: Current Issues, 1982, 9, 941-952.	2.3	21
44	Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53., 1997, 72, 155-159.		21
45	Novel Prognostic Groups in Thymic Epithelial Tumors: Assessment of Risk and Therapeutic Strategy Selection. International Journal of Radiation Oncology Biology Physics, 2008, 71, 420-427.	0.8	21
46	Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN) Tj ETQq0 0 0 rgBT /Overlock 1 Complementary and Alternative Medicine, 2018, 18, 22.	0 Tf 50 387 3.7	7 Td (5933/Gi) 21
47	FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting. International Journal of Molecular Sciences, 2019, 20, 2024.	4.1	21
48	Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective. EXCLI Journal, 2015, 14, 228-36.	0.7	21
49	Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease. Current Drug Targets, 2017, 18, 1179-1190.	2.1	21
50	Mutations in K-ras Codon 12 Detected in Plasma DNA Are Not an Indicator of Disease in Patients with Non-Small Cell Lung Cancer. Clinical Chemistry, 2005, 51, 1313-1314.	3.2	18
51	Quantitative predictivity of the transformationin vitroassay compared with the ames test. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1983, 12, 483-510.	2.3	17
52	Human Granulocyte-Macrophage Colony-stimulating Factor Is a Growth Factor Active on Human Ovarian Cancer Cells. Japanese Journal of Cancer Research, 1991, 82, 1196-1198.	1.7	17
53	Generation and Characterization of a Low-Degree Drug-Resistant Human Tumor Cell Line. Oncology, 1990, 47, 488-494.	1.9	16
54	Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. Journal of Thoracic and Cardiovascular Surgery, 2006, 131, 314-321.e3.	0.8	16

#	Article	IF	Citations
55	Effect of recombinant human tumor necrosis factor on A2774 human ovarian cancer cell line: Potentiation of mitoxantrone cytotoxicity. Gynecologic Oncology, 1991, 41, 52-55.	1.4	15
56	Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach. Current Medicinal Chemistry, 2015, 22, 3655-3675.	2.4	15
57	Prognostic role of K-Ras mutations in non-small cell lung cancer: Still an issue for open debate. Lung Cancer, 2006, 53, 393-395.	2.0	14
58	K-ras Mutations in Circulating DNA From Pancreatic and Lung Cancers. Pancreas, 2008, 37, 101-102.	1.1	14
59	Metabolic Disorder in Chronic Obstructive Pulmonary Disease (COPD) Patients: Towards a Personalized Approach Using Marine Drug Derivatives. Marine Drugs, 2017, 15, 81.	4.6	14
60	Potentiation of Topoisomerase I and II Inhibitors Cell Killing by Tumor Necrosis Factor: Relationship to DNA Strand Breakage Formation. Japanese Journal of Cancer Research, 1992, 83, 1132-1136.	1.7	13
61	Assay of phenacetin genotoxicity using in vitro and in vivo test systems. Journal of Toxicology and Environmental Health - Part A: Current Issues, 1985, 16, 355-377.	2.3	12
62	?7 nAChR in Airway Respiratory Epithelial Cells. Current Drug Targets, 2012, 13, 666-670.	2.1	12
63	Nicotine Changes Airway Epithelial Phenotype and May Increase the SARS-COV-2 Infection Severity. Molecules, 2021, 26, 101.	3.8	12
64	In vivo Cancer Imaging with Semiconductor Quantum Dots. Current Pharmaceutical Analysis, 2008, 4, 197-205.	0.6	11
65	DNA damage in mouse and rat liver by caprolactam and benzoin, evaluated with three different methods. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1989, 224, 379-384.	1.2	10
66	The role of the surgeon in translational research. Lancet, The, 2003, 362, 1082.	13.7	10
67	Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability. Current Cancer Drug Targets, 2003, 3, 109-118.	1.6	10
68	Potentiation of TNF-mediated cell killing by mitoxantrone. Biochemical Pharmacology, 1993, 46, 1199-1206.	4.4	9
69	Farnesyltransferase Inhibitors: Overview of their Action and Role in Solid Malignancy Therapy. Letters in Drug Design and Discovery, 2005, 2, 26-35.	0.7	9
70	Effects of vitamin E on liver DNA. Cancer Letters, 1984, 25, 163-170.	7.2	8
71	Malignant pleural mesothelioma: time for translational research. Lancet Oncology, The, 2004, 5, 591.	10.7	8
72	Use of Pharmacotherapy for Smoking Cessation in Italy. Archives of Internal Medicine, 2009, 169, 1927.	3.8	8

#	Article	IF	Citations
73	Biomarkers of DNA damage in COPD patients undergoing pulmonary rehabilitation: Integrating clinical parameters with genomic profiling. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 843, 111-117.	1.7	8
74	A New "Era―for the ?7-nAChR. Current Drug Targets, 2012, 13, 721-725.	2.1	8
75	The Sea Urchin, Paracentrotus lividus, as a Model to Investigate the Onset of Molecules Immunologically Related to the \hat{l} ±-7 Subunit of Nicotinic Receptors During Embryonic and Larval Development. Current Drug Targets, 2012, 13, 587-593.	2.1	8
76	DNA damage in liver of mice treated with N-nitrodimethylamine. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 103, 207-211.	1.1	7
77	Farnesyltransferase Inhibitors and Human Malignant Pleural Mesothelioma: A First-Step Comparative Translational Study. Clinical Cancer Research, 2005, 11, 2026-2037.	7.0	7
78	Flavonoids and Reduction of Cardiovascular Disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD). Current Medicinal Chemistry, 2019, 26, 7048-7058.	2.4	7
79	Detectabilityin vivo of stabilized intercalating agents with the alkaline elution technique comparison within vivo sister chromatid exchange induction. Journal of Applied Toxicology, 1983, 3, 58-62.	2.8	6
80	Use of the Semiconductor Nanotechnologies & https://www.amp;#x201C; Quantum Dots & https://www.cancerlmaging.Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 207-215.	1.6	6
81	Action plans and coping strategies in elderly COPD patients influence the result of pulmonary rehabilitation: an observational study. European Journal of Physical and Rehabilitation Medicine, 2017,	2.2	6
82	DNA damage in liver of rats treated with nitrofurantoin. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1982, 105, 377-382.	1.1	5
83	Potentiation by Tumor Necrosis Factor of Mitoxantrone Cytotoxicity to Human Ovarian Cancer Cell Lines. Japanese Journal of Cancer Research, 1992, 83, 684-687.	1.7	5
84	Induction of DNA double-strand breaks by 8-methoxycaffeine: cell cycle dependence and comparison with topoisomerase II inhibitors. Carcinogenesis, 1994, 15, 2491-2496.	2.8	5
85	Circumvention of Atypical Multidrug Resistance with Tumor Necrosis Factor. Japanese Journal of Cancer Research, 1994, 85, 135-138.	1.7	5
86	Interferon- $\hat{l}\pm$ or \hat{l}^2 potentiate platinum analogous in human glioblastoma cell lines. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 348, 131-135.	1.1	5
87	Interactions between taxol and camptothecin. Anti-Cancer Drugs, 1996, 7, 531-534.	1.4	5
88	Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. Mutagenesis, 2001, 16, 423-430.	2.6	5
89	Nonpeptidomimetic Farnesyltransferase Inhibitor RPR-115135 Increases Cytotoxicity of 5-Fluorouracil: Role of p53. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 220-226.	2.5	5

 $_{90}$ Editorial (Thematic Issue: Disease Control and Active and Healthy Ageing: New Paradigms of) Tj ETQq0 0 0 rgBT /Overlock $_{5}^{17}$ 50 62 To

#	Article	IF	CITATIONS
91	Daily Vegetables Intake and Response to COPD Rehabilitation. The Role of Oxidative Stress, Inflammation and DNA Damage. Nutrients, 2021, 13, 2787.	4.1	5
92	Commentary: Early Diagnosis of Lung Cancer: Where Do We Stand?. Oncologist, 2007, 12, 1433-1436.	3.7	4
93	Factors predicting poor survival after resection of stage IA non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2008, 136, 241-242.	0.8	4
94	Computed Tomography Screening for Lung Cancer in a High-Risk Population: Update on Current Status. Journal of the National Cancer Institute, 2008, 100, 1043-1044.	6.3	4
95	Psycho-cognitive assessment and quality of life in older adults with chronic obstructive pulmonary disease-carrying the rs4713916 gene polymorphism (G/A) of gene FKBP5 and response to pulmonary rehabilitation: a proof of concept study. Psychiatric Genetics, 2022, 32, 116-124.	1.1	4
96	Non-Small Cell Lung Cancer: From Cytotoxic Systemic Chemotherapy to Molecularly Targeted Therapy. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 231-245.	7.0	3
97	Smoking Out the Cholinergic Component in Lung Cancer. Clinical Cancer Research, 2008, 14, 6742-6743.	7.0	3
98	Microbiome in Chronic Obstructive Pulmonary Disease: Role of Natural Products Against Microbial Pathogens. Current Medicinal Chemistry, 2020, 27, 2931-2948.	2.4	3
99	Covid-19 and the role of smoking: the protocol of the multicentric prospective study COSMO-IT (COvid19 and SMOking in ITaly). Acta Biomedica, 2020, 91, e2020062.	0.3	3
100	DNA damage in dementia: Evidence from patients affected by severe Chronic Obstructive Pulmonary Disease (COPD) and meta-analysis of most recent literature. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2022, 878, 503499.	1.7	3
101	Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft. Cytokine, 1996, 8, 330-333.	3.2	2
102	RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces GO/G1 arrest only in serum starved cells. International Journal of Oncology, 2001, 18, 855-62.	3.3	2
103	Computed tomography screening for lung cancer. Cancer, 2008, 112, 2520-2521.	4.1	2
104	Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds. Marine Drugs, 2018, 16, 313.	4.6	2
105	Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Focus on Mutations - Part 1. Current Medicinal Chemistry, 2019, 26, 1721-1733.	2.4	2
106	Pharmacological Management of Chronic Obstructive Lung Disease (COPD). Evidence from a Real-World Perspective - Part 2. Current Medicinal Chemistry, 2019, 26, 1734-1745.	2.4	2
107	"Atypical―multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3). Journal of Cancer Research and Clinical Oncology, 1995, 121, 155-163.	2.5	1
108	Inflammation and thoracic surgery: a complex interaction. European Journal of Cardio-thoracic Surgery, 2007, 32, 950-950.	1.4	1

#	Article	IF	CITATIONS
109	Concluding Notes of Special Issue "?-7 Nicotinic Receptor (?7-nAChR): One Target Different Diseases― Current Drug Targets, 2012, 13, 726-727.	2.1	1
110	Networking for excellence in lung cancer: paper vs. research work. Lung Cancer, 2004, 43, 363-365.	2.0	0
111	Role of Tyrosine Kinase Inhibitor Molecules in Non Small Cell Lung Cancer:From Benchside to Bedside. Current Respiratory Medicine Reviews, 2007, 3, 159-167.	0.2	O
112	Editorial [Hot Topic: α7-Nicotinic Receptor (α7-nAChR): One Target Different Diseases (Guest Editors:) Tj ETQq0	0 0 0 rgBT 2.1	Oyerlock 10
113	DNA Fragmentation or Changes in Chromatin Conformation. Results with Two Model Systems: Promotion in Rat Liver Carcinogenesis and Proliferation in Mastocytes., 1988,, 195-202.		0